2413989

STTR PHASE II: LIVING PHARMACY FOR DIABETES AND OBESITY TREATMENT -THE BROADER IMPACTS OF THIS SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PHASE II PROJECT COULD BE BOTH SUBSTANTIAL AND MULTIFACETED, WITH FAR-REACHING IMPLICATIONS ACROSS THE ENTIRE SPECTRUM OF HEALTHCARE, EDUCATION, AND ENVIRONMENTAL STEWARDSHIP. THIS LIVING PHARMACY APPROACH IS AN INNOVATIVE AND TRANSFORMATIVE CELLULAR FACTORY METHOD OF ADMINISTERING TREATMENTS AND MANAGING CHRONIC DISEASES BY MAINTAINING STEADY-STATE DRUG LEVELS OVER LONG PERIODS OF TIME WITHOUT THE NEED FOR FREQUENT DOSING. BY SYNTHESIZING TREATMENTS DIRECTLY WITHIN THE BODY AND REPLACING DAILY, WEEKLY, OR MONTHLY DOSING WITH A SINGLE DOSE, THE TECHNOLOGY HAS THE POTENTIAL TO SIGNIFICANTLY ENHANCE PATIENT COMPLIANCE, OFFERING AN ALTERNATIVE TREATMENT MODALITY THAT MAKES THE DISEASE INVISIBLE TO DAILY LIFE. EDUCATIONALLY, THE PROPOSED TECHNOLOGY AS A PIONEERING WORK MAY SERVE AS A SPRINGBOARD FOR FOSTERING INNOVATION AND RESEARCH IN THE FIELD OF IMMUNO-SYNTHETIC BIOLOGY AND BIOTECHNOLOGY, PAVING THE WAY FOR THE NEXT GENERATION OF SCIENTISTS, RESEARCHERS, AND ENTREPRENEURS TO DRAW INSPIRATION FROM NATURE?S DESIGN FIRST. SCIENTIFICALLY, THE PLATFORM COULD ACT AS A TESTAMENT TO THE EXCITING POSSIBILITIES OF SYMBIOTIC SYNTHETIC BIOLOGY AND THE LIVING PHARMACY CONCEPT. THIS WORK SPANS THE FIELDS OF IMMUNOLOGY, MICROBIOLOGY, SYMBIOTIC BIOLOGY, AND SYNTHETIC BIOLOGY, WITH POTENTIAL DUAL APPLICATIONS IN THE DEFENSE INDUSTRY AND CANCER PREVENTION SPACE. THE PROPOSED PROJECT AIMS TO DEMONSTRATE THE SAFETY AND TOLERABILITY OF A NOVEL AND POTENTIALLY HARMLESS UNIVERSAL DESIGNER ORGANISM AS A LIVING PHARMACY TO TREAT DIABETES AND OBESITY IN CATS. SPECIFICALLY, THE PLAN IS TO DEMONSTRATE HOW A SINGLE INJECTION CAN BE EFFECTIVE FOR 12 WEEKS OR LONGER TO CONTROL BLOOD GLUCOSE AND WEIGHT GAIN FOR THE COMPANION ANIMAL MARKET. THIS WILL SERVE AS A MODEL FIRST, WITH THE EVENTUAL GOAL OF ENTERING THE HUMAN MARKET. THIS CELLULAR FACTORY PLATFORM COULD FACILITATE A NEW ERA OF COST-EFFECTIVE AND PATIENT-FRIENDLY TREATMENTS WITH FEWER SIDE EFFECTS AND SIGNIFICANTLY DECREASED CASCADING EFFECTS, PREVENTING SEVERE COMPLICATIONS AND THE ONSET OF CO-MORBIDITIES OF MANY CHRONIC DISEASES. THIS ADVANCEMENT HOLDS SUBSTANTIAL POTENTIAL TO CURB THE HEALTH CRISIS STAGED BY AN INCREASING NUMBER OF OBESE AND PREDIABETIC INDIVIDUALS IN THE NATION, THEREBY IMPROVING PUBLIC HEALTH AT A LARGE SCALE. THIS AWARD REFLECTS NSF'S STATUTORY MISSION AND HAS BEEN DEEMED WORTHY OF SUPPORT THROUGH EVALUATION USING THE FOUNDATION'S INTELLECTUAL MERIT AND BROADER IMPACTS REVIEW CRITERIA.- SUBAWARDS ARE PLANNED FOR THIS AWARD.

Simmbion

THE GOAL OF THIS FUNDING OPPORTUNITY, "NSF SMALL BUSINESS INNOVATION RESEARCH PHASE II (SBIR)/ SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAMS PHASE II", IS IDENTIFIED IN THE LINK: HTTPS://WWW.NSF.GOV/PUBLICATIONS/PUB_SUMM.JSP?ODS_KEY=NSF23516

47.084 - NSF Technology, Innovation, and Partnerships

National Science Foundation (NSF)

Baltimore, Maryland 21215-5201 United States

Single Zip Code

NSF Small Business Innovation Research / Small Business Technology Transfer Phase II Programs (SBIR/STTR Phase II) (23-516)

Amendment Since initial award the total obligations have decreased 100% from $1,000,000 to $0.